Browse our 650+ Publications​

Latest Publications

Positive and negative selection shape the human naïve B cell repertoire

Chen JW, et al.
Journal of Clinical Investigation
January 2022
Authors and Affiliates
Jeff W Chen 1, Jean-Nicolas Schickel 1, Nikolaos Tsakiris 1, Joel Sng 1, Florent Arbogast 1, Delphine Bouis 1, Daniele Parisi 1, Ruchi Gera 1, Joshua M Boeckers 1, Fabien R Delmotte 1, Margaret Veselits 2, Catharina Schuetz 3, Eva-Maria Jacobsen 3, Carsten Posovszky 3, Ansgar S Schulz 3, Klaus Schwarz 3, Marcus R Clark 2, Laurence Menard 1, Eric Meffre 1; 1 Department of Immunobiology, Yale University, New Haven, United States of America. 2 Department of Medicine, University of Chicago, Chicago, United States of America. 3 Department of Pediatrics and Adolescent Medicine, Ulm University, Ulm, Germany.

Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy

Mills BN, et al.
Clinical Cancer Research
January 2022
Authors and Affiliates
Bradley N Mills 1, Haoming Qiu 2,3, Michael G Drage 4, Chunmo Chen 4, Jocelyn S Mathew 1, Jesse Garrett-Larsen 1, Jian Ye 1, Taylor P Uccello 5, Joseph D Murphy 5, Brian A Belt 1, Edith M Lord 3,5, Alan W Katz 2,3, David C Linehan 1,3, Scott A Gerber 6,3,5; 1 Department of Surgery, University of Rochester Medical Center, Rochester, New York. 2 Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York. 3 Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York. 4 Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York. 5 Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York. 6 Department of Surgery, University of Rochester Medical Center, Rochester, New York. scott_gerber@urmc.rochester.edu.

Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids

Meng Q, et al.
Journal for ImmunoTherapy of Cancer
January 2022
Authors and Affiliates
Qingda Meng #,1, Shanshan Xie #,1, G Kenneth Gray 2, Mohammad H Dezfulian 3, Weilin Li 1, Ling Huang 1, Dipikaa Akshinthala 1, Elizabeth Ferrer 1, Catherine Conahan 1, Sofia Perea Del Pino 1, Joseph Grossman 1, Stephen J Elledge 3, Manuel Hidalgo 4, Senthil K Muthuswamy 5; 1 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. 2 Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA. 3 Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. 4 Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA smuthusw@bidmc.harvard.edu mah4006@med.cornell.edu. 5 Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA smuthusw@bidmc.harvard.edu mah4006@med.cornell.edu. # Contributed equally.

Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer

Chen M, et al.
Nature Communications
January 2022
Authors and Affiliates
Ming Chen #,1,2,3,4, Runzhe Chen #,5,6,7, Ying Jin #,8,9,10, Jun Li #,7, Xin Hu #,7, Jiexin Zhang #,11, Junya Fujimoto 12, Shawna M Hubert 6,7, Carl M Gay 6, Bo Zhu 6,7, Yanhua Tian 6,7, Nicholas McGranahan 13, Won-Chul Lee 7, Julie George 14 15, Xiao Hu 8,9,10, Yamei Chen 8,9,10, Meijuan Wu 8,9,10, Carmen Behrens 6, Chi-Wan Chow 12, Hoa H N Pham 16, Junya Fukuoka 16, Jia Wu 17, Edwin Roger Parra 12, Latasha D Little 7, Curtis Gumbs 7, Xingzhi Song 7, Chang-Jiun Wu 7, Lixia Diao 11, Qi Wang 11, Robert Cardnell 6, Jianhua Zhang 7, Jing Wang 11, Xiuning Le 6, Don L Gibbons 6, John V Heymach 6, J Jack Lee 18, William N William Jr 6, Chao Cheng 19, Bonnie Glisson 6, Ignacio Wistuba 12, P Andrew Futreal 7, Roman K Thomas 20,21,22, Alexandre Reuben 23, Lauren A Byers 24, Jianjun Zhang 25,26; 1 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China. chenming@sysucc.org.cn. 2 The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China. chenming@sysucc.org.cn. 3 Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. chenming@sysucc.org.cn. 4 Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, Zhejiang, 310022, China. chenming@sysucc.org.cn. 5 Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, Guangdong, 510060, China. 6 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. 7 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. 8 The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, 310022, China. 9 Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China. 10 Zhejiang Key Laboratory of Radiation Oncology, Hangzhou, Zhejiang, 310022, China. 11 Department of Bioinformatics and Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. 12 Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. 13 Cancer Research United Kingdom-University College London Lung Cancer Centre of Excellence, London, WC1E6BT, UK. 14 Department of Translational Genomics, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, 50931, Germany. 15 Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Cologne, 50937, Cologne, Germany. 16 Department of Pathology, Nagasaki University Graduate school of Biomedical Sciences, Nagasaki, Japan. 17 Department of Image Physics, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. 18 Department of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. 19 Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, Texas, 77030, USA. 20 Department of Translational Genomics, Medical Faculty, University of Cologne, Cologne, 50931, Germany. roman.thomas@uni-koeln.de. 21 Department of Pathology, Medical Faculty, University Hospital Cologne, Cologne, 50931, Germany. roman.thomas@uni-koeln.de. 22 DKFZ, German Cancer Research Center and German Cancer Consortium (DKTK), Heidelberg, 69115, Germany. roman.thomas@uni-koeln.de. 23 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. areuben@mdanderson.org. 24 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. lbyers@mdanderson.org. 25 Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. jzhang20@mdanderson.org. 26 Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, USA. jzhang20@mdanderson.org. # Contributed equally.

A simple assay to quantify mycobacterial lipid antigen-specific T cell receptors in human tissues and blood

Zhou AX, et al.
January 2022
Authors and Affiliates
Angela X Zhou 1,2, Thomas J Scriba 3, Cheryl L Day 4, Deanna A Hagge 5, Chetan Seshadri 1,2; 1 Department of Medicine, University of Washington, Seattle, Washington, United States of America. 2 Tuberculosis Research and Training Center, University of Washington, Seattle, Washington, United States of America. 3 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. 4 Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America. 5 Mycobacterial Research Laboratories, Anandaban Hospital, Kathmandu, Nepal.

Epstein-Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report

Aran A, et al.
Frontiers in Immunology
January 2022
Authors and Affiliates
Andrea Aran 1, Vicente Peg 2, Rosa Maria Rabanal 3, Cristina Bernadó 4, Esther Zamora 5, Elisa Molina 1, Yago A Arribas 1, Joaquín Arribas 4,6,7,8, José Pérez 9, Carme Roura-Mir 1, Montserrat Carrascal 10, Javier Cortés 5 9, Mercè Martí 1; 1 Immunology Unit, Department of Cell Biology, Physiology and Immunology, Institut de Biotecnologia i Biomedicina (IBB), Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. 2 Translational Molecular Pathology, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. 3 Unitat de Patologia Murina i Comparada, Department of Animal Medicine and Surgery, Veterinary Faculty, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. 4 Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. 5 Breast Cancer Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain. 6 Cancer Research Program, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain. 7 Centro de Investigación Biomédica en Red de Cáncer, Madrid, Spain. 8 Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. 9 International Breast Cancer Center (BCC), Quironsalud Group, Barcelona, Spain. 10 Biological and Environmental Proteomics, Institute of Biomedical Research of Barcelona, Spanish National Research Council, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IIBB-CSIC/IDIBAPS), Barcelona, Spain.

Impact of T Cell Repertoire Diversity on Mortality Following Cord Blood Transplantation

Milano F, et al.
Frontiers in Immunology
January 2022
Authors and Affiliates
F Milano 1,2, R O Emerson 3, R Salit 1,2, K A Guthrie 1, L A Thur 1, A Dahlberg 1,4, H S Robins 1,3, C Delaney 1,4; 1 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 2 Department of Medicine, University of Washington School of Medicine, Seattle, WA, United States. 3 Adaptive Biotechnologies, Seattle, WA, United States. 4 Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States.

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial

Forde PM, et al.
Nature Medicine
January 2022
Authors and Affiliates
Patrick M. Forde 1,2,14, Valsamo Anagnostou 1,2,14, Zhuoxin Sun 3,4,14, Suzanne E. Dahlberg 5, Hedy L. Kindler 6, Noushin Niknafs 1, Thomas Purcell 7, Rafael Santana-Davila 7, Arkadiusz Z. Dudek 8, Hossein Borghaei 9, Mara Lanis 1, Zineb Belcaid 1, Kellie N. Smith 1,2, Archana Balan 1, James R. White 1, Christopher Cherry 1, I. K. Ashok Sivakumar 10, Xiaoshan M. Shao 10,11, Hok Yee Chan 1,2, Dipika Singh 1,2, Sampriti Thapa 1,2, Peter B. Illei 1,12, Drew M. Pardoll 1,2, Rachel Karchin 1,10,11, Victor E. Velculescu 1,2,11,12, Julie R. Brahmer 1,2 and Suresh S. Ramalingam 13; 1 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. pforde1@jhmi.edu. 2 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. pforde1@jhmi.edu. 3 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. 4 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. vanagno1@jhmi.edu. 5 ECOG-ACRIN Biostatistics Center, Boston, MA, USA. 6 Frontier Science Foundation, Boston, MA, USA. 7 Boston Children's Hospital, Boston, MA, USA. 8 University of Chicago Medicine, Chicago, IL, USA. 9 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 10 University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 11 Metro-Minnesota Community Oncology Research Consortium, St. Louis Park, MN, USA. 12 Fox Chase Cancer Center, Philadelphia, PA, USA. 13 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 14 Institute for Computational Medicine, Johns Hopkins University, Baltimore, MD, USA. 15 Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA. 16 Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 17 Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA. # Contributed equally.

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia.

Pulsipher MA, et al.
Blood Cancer Discovery
January 2022
Authors and Affiliates
Michael A. Pulsipher1, Xia Han2, Shannon L. Maude3,4, Theodore W. Laetsch3,4,5, Muna Qayed6,7, Susana Rives8, Michael W. Boyer9, Hidefumi Hiramatsu10, Gregory A. Yanik11, Tim Driscoll12, G. Doug Myers13, Peter Bader14, Andre Baruchel15,16, Jochen Buechner17, Heather E. Stefanski18, Creton Kalfoglou2, Kevin Nguyen2, Edward R. Waldron2, Karen Thudium Mueller2, Harald J. Maier19, Gabor Kari19, and Stephan A. Grupp3,4 1Section of Transplantation and Cellular Therapy, Children’s Hospital Los Angeles Cancer and Blood Disease Institute, USC Keck School of Medicine, Los Angeles, California. 2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey. 3Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 4Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania. 5Department of Pediatrics, The University of Texas Southwestern Medical Center, Dallas, Texas. 6Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia. 7Aflac Cancer and Blood Disorders Center, Healthcare of Atlanta, Atlanta, Georgia. 8Pediatric Hematology, Hospital Sant Joan de Déu de Barcelona, Fundació Sant Joan de Déu, Barcelona, Spain. 9Department of Pediatrics and Internal Medicine, University of Utah, Salt Lake City, Utah. 10Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto City, Japan. 11Michigan Medicine Bone Marrow Transplant and Leukemia, C.S. Mott Children’s Hospital, Ann Arbor, Michigan. 12Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina. 13Pediatric Hematology and Oncology, Children’s Mercy Hospital; University of Missouri—Kansas City School of Medicine, Kansas City, Missouri. 14Division for Stem Cell Transplantation, Immunology and Intensive Care Medicine Hospital for Children and Adolescents University Hospital Frankfurt, Frankfurt, Germany. 15Pediatric Hemato-Immunology Department, Hôpital Universitaire Robert Debré (APHP), Paris, France. 16Université de Paris et Institut de Recherche SaintLouis (EA3518), Paris, France. 17Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway. 18Department of Pediatrics, The University of Minnesota Medical School, Minneapolis, Minnesota. 19Novartis Pharmaceuticals Corporation, Basel, Switzerland.
Previous Next